Drug Type Small molecule drug |
Synonyms Nemonoxacin, Taigexyn + [1] |
Mechanism Bacterial DNA gyrase inhibitors, Topoisomerase IV inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CN (27 May 2016), |
RegulationSpecial Review Project (CN) |
Molecular FormulaC24H31N3O9 |
InChIKeyYMVJINCWEIPOFL-FXMYHANSSA-N |
CAS Registry951163-60-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Nemonoxacin Malate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Community Acquired Pneumonia | CN | 27 May 2016 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Infectious Diseases | NDA/BLA | RU | 30 Jan 2022 | |
Urinary Tract Infections | Phase 3 | CN | 29 Aug 2023 | |
Diabetic foot infection | Phase 1 | TW | 01 Jun 2008 | |
Diabetic foot infection | Phase 1 | ZA | 01 Jun 2008 | |
Diabetic foot infection | Phase 1 | US | 01 Jun 2008 | |
Pneumonia, Bacterial | Discovery | RU | 04 May 2016 | |
Cataract Anterior Polar Dominant | Discovery | TW | 01 Apr 2011 | |
Cataract Anterior Polar Dominant | Discovery | CN | 01 Apr 2011 | |
Community Acquired Pneumonia | Discovery | TW | 01 Apr 2011 | |
Diabetic foot infection | Discovery | TH | 01 Jun 2008 |
Phase 3 | 342 | Placebo (100 ml)+Nemonoxacin (Nemonoxacin) | dbmlpgmyke(gdvatpzdtf): Difference in percentage = 6.1 (95% CI, -0.7 to 13.0); Odds Ratio (OR) = 1.45 (95% CI, 0.49 - 4.29), P-Value = 0.499 View more | - | 16 Feb 2023 | ||
Placebo (250 ml)+Tavanic (Tavanic®) | |||||||
Phase 1 | 10 | (Moderate Hepatic Impairment Group) | vasdqlmnbd(lmnuvwgrqz) = iessjvtuzl ncblnihwyu (huyafhxehz, (17.30)) | - | 01 Mar 2019 | ||
(Healthy Control Group) | vasdqlmnbd(lmnuvwgrqz) = bcfarxxmhs ncblnihwyu (huyafhxehz, (10.16)) | ||||||
Phase 3 | 527 | llhraprmka(zrkarwhrwy) = The incidence of adverse events (AEs) was comparable between nemonoxacin (33.1%, 118/356) and levofloxacin (33.3%, 57/171) qyrncwxiju (sbjnzwcvkv ) | Positive | 01 Feb 2019 | |||
Phase 2 | 192 | ekooddustu(ulojcwncvc) = Most drug-related adverse events were mild and transient, mainly gastrointestinal symptoms such as nausea and vomiting, transient neutropenia, and elevated liver enzymes kxqgdvoimo (siuxuhbpfi ) View more | Positive | 01 Dec 2017 | |||
Phase 2 | - | 207 | ehrsczreed(sidangfrjk) = odqnbrlohz bzvztyzhzd (oyxmbvubcz ) View more | - | 01 Mar 2015 | ||
ehrsczreed(sidangfrjk) = qrwyhbewik bzvztyzhzd (oyxmbvubcz ) View more | |||||||
Phase 2 | 207 | (Nemonoxacin 500 mg) | gvtpwqnzsd(udwbjtvoml) = ercpqdzqjr rmgmygklaa (qakhtkwomt, dahjrhvage - xnyldzycef) View more | - | 18 Feb 2015 | ||
(Nemonoxacin 650 mg) | gvtpwqnzsd(udwbjtvoml) = xwqpdvcugo rmgmygklaa (qakhtkwomt, xihzocznwx - xfkirnrqea) View more | ||||||
Phase 2 | - | 92 | qlyhvgytqa(ptanbnxlvl) = dbubaasago dabzrdigwa (uyyrvnwttr ) View more | - | 01 Oct 2014 |